Hansa Biopharma
Hansa Biopharma appoints Fredrik Röök as VP Business Development
June 11, 2026Business Development Hansa Biopharma
Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development, as of 17 August. Röök will …
Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International
December 17, 2025General Manager Europe and International, Hansa Biopharma, vice president
Hansa Biopharma, a commercial-stage biopharmaceutical company focusing on rare immunological conditions, has announced the appointment of Max Sakkajja as Vice …
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
August 4, 2025Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
Hansa Biopharma bolsters leadership team with new executive appointments
July 31, 2025Research and Development Chief Human Resources Officer, Chief Legal Officer, Corporate, Executive Leadership Team, Hansa Biopharma, Vice President Corporate Affairs
Hansa Biopharma has announced three senior leadership appointments to support its global expansion as well as pre-commercial activities in the …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
June 10, 2025Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
May 15, 2025Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Hansa Biopharma appoints Renée Aguiar-Lucander as CEO
April 24, 2025Research and Development CEO, Corporate, Hansa Biopharma, appointment, immunology
Swedish biopharma company, Hansa Biopharma, has announced the appointment of new chief executive officer (CEO) Renée Aguiar-Lucander, replacing Søren Tulstrup …
